Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL16860553 | 0.96 | CYP3A4 (0.32) | CYP3A4ALDH1A1AHRCA1CA2 | |
| SCHEMBL9703822 | 0.82 | CYP3A4 (0.31) | CYP3A4ALDH1A1 | |
| SCHEMBL9485161 | 0.78 | ALDH1A1 (0.40) | CYP3A4ALDH1A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3684155 | 0.75 | CES1 (0.37) | ALDH1A1AHR | |
| SCHEMBL6846394 | 0.73 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL7276600 | 0.71 | UCHL1 (0.41) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL9438330 | 0.68 | CA1 (0.57) | CA1CA2CA12CA9CA7 | |
| SCHEMBL454552 | 0.67 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL9360881 | 0.67 | CYP3A4 (0.35) | CYP3A4ALDH1A1AHR | |
| SCHEMBL438003 | 0.64 | CYP3A4 (0.56) | CYP3A4ALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365678-B2 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl) cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates | ASTRAZENECA AB (SE) | 2025-07-22 | — | — | US | claimed |
| CN-119534412-A | Method for rapidly detecting out-of-standard methanol in gasoline on site | 福建师范大学 | 2025-02-28 | — | — | CN | claimed |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-01-02 | — | — | US | claimed |
| CN-118414345-A | Oligosaccharide compounds and complexes | 生物技术公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4402150-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | claimed |
| CN-113195728-B | Pharmaceutical process and intermediates | 阿斯利康(瑞典)有限公司 | 2024-07-16 | — | — | CN | claimed |
| EP-4286394-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | claimed |
| CN-115417849-B | Method for catalytic synthesis of 3-isochromone | 河南省化工研究所有限责任公司 | 2023-09-26 | — | — | CN | claimed |
| CN-116640066-A | Method for synthesizing alkyl unnatural amino acid derivative by photocatalysis | 大连理工大学 | 2023-08-25 | — | — | CN | claimed |
| CN-116601163-A | Protected disaccharides, methods for their preparation, their use in the synthesis of zwitterionic oligosaccharides and conjugates thereof | 巴斯德研究所 | 2023-08-15 | — | — | CN | claimed |
| US-6187931-B1 | Process for making fluorophthalimides | ALBEMARLE CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-0558974-B1 | Process for manufacturing unsaturated fatty acids | K D PHARMA GMBH (DE) | 1996-01-31 | — | — | EP | claimed |
| US-5362895-A | Method of recovering unsaturated fatty acids | K.D. PHARMA GMBH (DE) | 1994-11-08 | — | — | US | claimed |
| EP-0558974-A1 | Process for manufacturing unsaturated fatty acids | K.D. PHARMA GmbH (DE) | 1993-09-08 | — | — | EP | claimed |
| US-4273674-A | HALOGENATED PHTHALIMIDES | GENERAL ELECTRIC COMPANY (US) | 1981-06-16 | — | — | US | claimed |
| US-4256507-A | FLAVANTHRONE, PYRANTHRONE, INDANTHRONE, INDIGO, QUINACRIDONE, PERYLENE DIANHYDRIDE OR DIIMIDE PIGMENTS SUBSTITUTED WITH PHTHALIMIDO-METHYL GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | claimed |
| EP-0014458-A1 | Pigment preparations for lacquers and printing dyes | BASF Aktiengesellschaft (DE) | 1980-08-20 | — | — | EP | claimed |
| US-4208489-A | AN ALKALI METAL SALT AND A TETRAHALOGENOPHTHALIMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1980-06-17 | — | — | US | claimed |
| US-4204428-A | Thermal detection system for failure in electrical apparatus and thermal detecting paint compositions | GENERAL ELECTRIC COMPANY (US) | 1980-05-27 | — | — | US | claimed |
| US-4035383-A | Eutectic process for preparing polychloro copper phthalocyanine | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365678-B2 | Pharmaceutical process for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl) cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b] pyridine and intermediates | TPMT, CYP3A7, HTR7 | CYP3A4 50/4885ALDH1A1 2596/4885AHR 2676/4885 |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, FUT6, MAN2B2 | CYP3A4 4773/4885ALDH1A1 2911/4885AHR 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.